期刊文献+

脓毒症凝血功能紊乱的药物治疗进展 被引量:5

原文传递
导出
摘要 脓毒症(sepsis)是感染因素所致的全身炎症反应综合征,进一步发展可导致脓毒性休克、多器官功能障碍综合征(multiple organ dysfunction syndrome,MODS)。目前,因严重感染引起的脓毒症仍是世界范围内非心脏病ICU患者的首要死亡原因。美国流行病学资料显示,近20年来脓毒症发生率由82.7/10万上升至240.4/10万,病死率为28%,而严重脓毒症的病死率则高达30%~50%;
出处 《中华外科杂志》 CAS CSCD 北大核心 2009年第1期62-64,共3页 Chinese Journal of Surgery
基金 基金项目:国家重点基础研究发展规划项目(2005CB522602)
  • 相关文献

参考文献33

  • 1姚咏明,刘峰.外科严重感染及其并发症的防治策略[J].中华外科杂志,2006,44(9):577-580. 被引量:14
  • 2Martin GS, Mannino DM, Eaton S, et al. The epidemiology of sepsis in the United States from 1979 through 2000. N Eng J Med, 2003, 348:1546-1554.
  • 3Danai PA, Sinha S, Moss M, et al. Seasonal variation in the epidemiology of sepsis. Crit Care Med, 2007, 35:410-415.
  • 4姚咏明,孟海东.严重脓毒症抗凝治疗的新认识[J].中华儿科杂志,2006,44(8):569-572. 被引量:12
  • 5武子霞(综述),李银平,姚咏明(审校).活化蛋白C的生物学活性及其作用机制研究进展[J].中国危重病急救医学,2007,19(3):182-185. 被引量:22
  • 6Taylor FB Jr, Stearns-Kurosawa DJ, Kurosawa S, et al. The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis. Blood, 2000, 95 : 1680-1686.
  • 7Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med, 2001, 344:699-709.
  • 8Levi M, van der Poll T. Recombinant human activated protein C : current insights into its mechanism of action. Crit Care, 2007, 11 Suppl 5 :S3.
  • 9van Veen SQ, Levi M, van Vliet AK, et al. Peritoneal lavage with activated protein C alters compartmentalized coagulation and fibrinolysis and improves survival in polymierobial peritonitis. Crit Care Med, 2006, 34:2799-2805.
  • 10Vincent JL. Drotrecogin alfa (activated) in the treatment of severe sepsis. Curr Drug Saf, 2007, 2:227-231.

二级参考文献97

共引文献234

同被引文献64

  • 1容剑雨,林高彦.血必净治疗肺结核肺心病28例临床观察[J].现代医药卫生,2006,22(14):2194-2194. 被引量:2
  • 2苏艳丽,王红,张淑文.脓毒症的凝血功能紊乱与抗凝治疗研究进展[J].中国危重病急救医学,2006,18(11):698-701. 被引量:45
  • 3Rippe JM,Train RS,Fink MP,editors.Intensive care medicine[M].Boston:Little Brown,1996:1857-1877.
  • 4Wilmot LA.Shock:Early recognitionand management[J].Emerg Nurs,2010,36(2):134-139.
  • 5Williams SG,Wight DJ,Tan LB.Management of cardiogenic shock compicating acute myodardial infarction:towards evidence base medical practice[J].Heart,2000,83(2):621-626.
  • 6Kontra JM.Evidence-based management of severe sepsis and septic shock[J].J Lancaster Hosp,2006,1(2):39-46.
  • 7Dellinger RP,Levy MM,Carlet JM,et al.Surviving sepsis campaign:international guidelines for management of severe sepsis and septic shock[J].Intensive Care Med,2008,34(1):17-60.
  • 8Bertrand ME,McFadden E.Cardiogenic shock:is there light at the end of the tunnel[J] ? J Am Coll Cardiol,2003,42(8):1387-1388.
  • 9Cantor WJ,Brunet F,Ziegler CP,et al.Immediate angioplasty after thrombolysis:a systematic review[J].CMAJ,2005,173(12):1473-1481.
  • 10Wadhwa S.Cardiogenic shock-current status[J].JIACM,2007,8(2):146-149.

引证文献5

二级引证文献57

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部